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Factor lXa Inhibition Contributes to the Heparin Effect
Suzette B6guin, Fr6d6rique Dol",  and H. Coenraad Hemker
From the Department of Biochemistry, University of Limburg, Maastricht, The Netherlands
Summary
We investigated whether the inactivation of factor IXa con-
tributes to the partial inhibition of thrombin formation that is
observed at therapeutic concentrations of heparin. The action of
standard unfractionated heparin (0.05 U/ml) on thrombin forma-
tion in the intrinsic system was compared to that of a mixture of
dermatan sulfate (DS) and a synthetic pentasaccharide (PS). DS
enhances the action of heparin cofactor II which inhibits throm-
bin only. PS specifically enhances the anti-factor Xa activity of
antithrombin III (AI III). The concentrations of DS and PS were
chosen so as to obtain equal anti-thrombin and anti-factor Xa
activities as in 0.05 U/ml heparin. An extra inhibitory effect of
heparin over the mixture is observed in situations where free
factor IXa, not bound to factor VIIIa and phospholipid, limits
the rate of thrombin formation, notably in contact activated
plasma. We conclude that the inactivation of free factor IXa by
heparin contributes importantly to the inhibition of thrombin
formation in the intrinsic system such as e. g. measured in the
activated partial thromboplastin time.
lntroduction
Heparin is known to catalyse the inactivation of the free serine
proteases of blood coagulation by AT III (7,2). -lhe amount of
free thrombin that develops in clotting plasma is greatly reduced
in the presence of heparin. This phenomenon can be either due to
increased inactivation of the thrombin formed or to inhibition of
prothrombin activation. This latter inhibition may be due to
enhanced inactivation of activated factor X (factor Xa) or to
inhibition of factors upstream in the coagulation cascade. Factor
Xa inactivation has been assumed to be particularly important
with low molecular weight heparins because they inactivate
isolated factor Xa more readily than thrombtn (2). We have
found that in a thromboplastin activated system unfractionated
heparin and most low molecular weight heparins exert their effect
almost exclusively via inhibition of thrombin (3, 4). A synthetic
pentasaccharide (PS) identical to the main AT III binding site of
heparin (5) and other very low molecular weight heparins do not
or hardly affect thrombin breakdown but act via the inactivation
of prothrombinase (3).
In the intrinsic (contact activated-)system, all heparins post-
pone and inhibit prothrombin conversion. McNeely and Griffith
(6) found that complete inhibition of thrombin generation by
0.5 U/ml heparin is not due to inhibition of the contact system.
The question that we ask here is whether factor IXa inactivation
is (co-)responsible for the partial inhibition seen at partially
inhibiting heparin concentrations such as they occur in patients.
Whether heparin in the intrinsic system acts also via enhanced
inactivation of factor IXa is important for the interpretation of
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the effect of heparin on the activated partial thromboplastin time,
the common test for estimating the effect of heparin administra-
tion in patients. We found earlier that the increase of the lag
phase of thrombin formation in the intrinsic system is due to the
inhibition of thrombin-mediated factor VIII activation and we
surmised that the inhibition of prothrombin conversion could be
due to the action of heparin-antithrombin III on factor IXa under
these conditions (4). Our conclusions were based on calculation of
prothrombin conversion rates from thrombin generation curves
(7). Ofosu and his group came to similar conclusions by measur-
ing prothrombin conversion by immunological methods (8, 9).
In the present study we compare the action of heparin to that
of a mixture of PS and DS that has the same anti-thrombin and
anti-factor Xa activity as the heparin. DS, that acts via heparin
cofactor II, inhibits thrombin only (10), and the inhibitory action
of PS is almost exclusively confined to factor Xa (11). A mixture
of PS and DS therefore can mimick the action of heparin with the
exclusion of its effect on factor IXa. A larger effect of heparin
compared to the DS-PS mixture thus can be used to spot the
situations where factor IXa limits the rate of thrombin formation.
Methods
Heparin (4th international standard, f94 Ulmg), PS (batch IC 83.7423
at 800 International anti-factor Xa U/mg) and DS (batch IC 87.374) were
gifts of Dr. Jean Choay (Centre Choay, Gentilly, France). The plasma
used was pooled platelet poor citrated plasma from 20 healthy donors,
stored in 1 ml portions at -80" C. It was defibrinated with reptilase before
use Isolated clotting factors were obtained according to the following
references: factor IXa: 12; factor VIII: 13; thrombin: 14; human brain
thromboplastin: 15; phospholipid (80% phosphatidyl choline, 20o/o phos-
phatidyl serine) 16. S2238 (HD-phe-pip-arg-p-nitrophenyl acetate, 2 HCI)
was obtained from KabiMtrum. Stockholm. Sweden.
The anti-factor Xa activities of PS and standard heparin dissolved in
normal plasma were determined according to refs. 17 and 18.
Thrombin generation was assessed by spectrophotometdc determina-
tion of the amidolytic activity on 52238 that develops in plasma after
triggering thrombin formation. The 400 pl reaction mixture contained
250 pl of plasma and 85 pl of buffer A (Tiis-HCl 50 mM, pH 7.35, 0.1 M
NaCl, 0.5% egg albumin) with the heparin or other inhibitors so as to
obtain the final concentrations indicated and 65 pl of the triggering
solution.
The triggering solution consisted of 100 mM CaCl2 in buffer A with a)
for the extrinsic pathway: human brain thromboplastin diluted so as to
make the uninhibited, undefibrinated reaction mixture coagulate in
78-82 s, b) for the intrinsic pathway: 15 pg/ml of kaolin plus 7.2 pM of
phospholipid, c) complete intrinsic factor X activator or d) incomplete
intrinsic factor X activator. The complete factor X activating enzyme
complex ("complete tenase"), consisted of factor IXa (7.2 nM), factor
VIIIa (10 U/ml, i. e. 10 U/ml of factor VIII with 2.5 nM thrombin added
2 min before use) and 7.2 pM phospholipid. The incomplete factor X
activator ("incomplete tenase") contained no factor VIIa but was other-
wise identical Factors added in the course of the experiment were
dissolved in 10 pl of buffer A so as to obtain the final concentration
indicated.
The amidolytic activity generated in the plasma mixtures was deter-
mined in 10 pl aliquots that were transferred to 490 ml buffer A, at
pH7.9, containing 0 2 mM 52238 and 20 mM EDTA. After 2 mrn,52238
conversion was stopped by adding 300 pl of concentrated acetic acid and
the absorbancy at 405 nm was determined For details on the method see
ref. 7.
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Fqq.3 Thrombin generation in plasma after triggering with complete
tenase. Tiigger: factor lxa (1.2 nM), factor^Vllla (1.6 U/ml), phos-
pholipid (1.2 pM) (final concentrations) and Ca'* (see methods). Symbols
as in Fig. 1
1 0 0
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Fig.4 Thrombin generation in plasma after triggering with incomplete
tenase. Tiigger: factor IXa, phospholipid and Ca'*. Final concentrations
as in Fig.3, symbols as in Fig. 1
calculation of free thrombin concentrations is not dependent upon any
assumption except that of a pseudo-first order reaction of thrombin with
o.2-macroglobulin with the given rate constant This is verified by the
observation that the calculated thrombin concentrations eventually
descend to the zero level.
Results
We used a heparin concentration of 0.05 Ulml (0.26 pg/ml);
this inhibits thromboplastin-induced thrombin formation about
50%, mainly through increasing thrombin breakdown (a). In
order to mimick the anti-factor X a effect of the heparin we added
PS to obtain the same anti-factor Xa activity as was present in the
heparin solution, i.e. 0.05 anti-factor Xa-units/l (0.06 pg/ml).
This has no anti-factor IXa action (11). From experiments on
plasmas deficient in factor IX we found previously that factor IX
activation contributes only negligibly to thromboplastin-induced
thrombin formation under our experimental conditions (20). The
inhibition caused by 0.05 U/ml of heparin, that is not caused by
the PS added must therefore be due to thrombin inactivation. So
we sought the concentration of DS that, in the presence of this
amount of PS, would give 50% inhibition of the thrombin peak in
the extrinsic system. This was 1.25 pglml (Fig. 1). In this way the
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Fig 1 Thrombin generation in thromboplastin activated plasma Tiig-
ger: Diluted human brain thromboplastin as indicated under methods.
O----O contro l ;  a--- -a DS 1.25 pg/ml -  PS 0.06 pg/ml;  A--- -A
heoarin 0.05 U/ml
200
1 0 0
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TIME ( min )
F4g 2 Thrombin generation in contact activated plasma. Tiigger: Ca2+,
kaolin and phospholipid, as indicated under methods, symbols as in Fig. 1
At any time l, the amidolytic activity (,4r) represents the activity of
thrombin (!) and the cr2-macroglobulin-thrombin complex (!,). This
latter complex builds up during the reaction and causes final levels of
amidolytic activity equivalent to about 50 nM thrombin in the control and
proportionally lower when heparin or DS favour the action of AT III or
HC II. Because thrombin carries the physiologically important activities
we prefer to give the time course of thrombin rather than that of
amidolytic activity and therefore we subtracted C, from ,4, in order to
obtain ?,. Under our conditions, the o2-macroglobulin-thrombin complex
has a molar activity on 52238 of 0 55 times that of thrombin (7). The
concentration of the complex is obtained from an exact solution (see ref
19) of the differential equations that govern the generation of thrombin
(!) and the o2-macroglobulin-thrombin complex (Q, vrz:
d l i l r @ : s @ - G t + L ) ' r ( ! )
d td l c (o  :  b . r@
A O :  r @  +  o . s s . c ( 0
Where g(f is the thrombin generation from prothrombin as a function of
time; k1 the pseudo first order constant of the thrombin-antithrombin
reaction and futhe pseudo first order reaction constant of the inactivation
of thrombin by o2-macroglobulin; fu, was determined to be 0.23 min 1, in
the absence as well as in the presence of heparin, PS and DS, by the
method of ref.7
For all practical purposes the solution can be visualized as a solution of
the equat ions e,  *  o, :  Q + k2'  Lt '  (A,  -  Qt)  and eo :  0.  The
1 0
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Fig.5 Thrombin generation in plasma after triggering with incomplete
teiase. Effect of addition of factor VIIIa (1'6 U/m1) at t : 2' Symbols as
in Fig.1. See text for experimental details
Flg.6 Thrombin generation in plasma after triggering with incomplete
teiase. Effect of addition of factor VIIIa (1'6 U/ml) at t : 2 and
factor IXa (1.2 nM) at t : 3. Symbols as in Fig l' See text tor
experimental details
PS-DS mixture is limited to inactivation of thrombin by DS and
factor Xa by PS. We choose the concentrations of PS and DS so
as to make these effects equal to respectively the anti-factor Xa
and the anti-thrombin effect of 0.05 U/ml of heparin'
An extra effect of heparin over the PS-DS mixture is seen in
contact activated plasmi and also when thrombin formation is
started with factor IX a in the absence of factor VIII a (Figs ' 2 and
induced disappearance of factor IXa. The presence of factor
VIIIa (Fig.3) prevents the extra inhibition, so heparin must
inhibit irei faCtor IXa, not bound to factor VIIIa and phos-
pholipid. Thrombin formation triggered without added factor
VIII; is not immediate as with complete tenase but shows a lag
phase. Both in the presence and in the absence of inhibitors, the
iag phase ends abruptly upon addition of factor VIIIa (Fig' 5)'
str-owing that factor VIII activation is compulsory' When factor
VIIIa ii added after zeto time, the resulting thrombin formation
is much smaller when heparin is present in the medium than with
the PS-DS mixture. This indicates that during the absence of
factor MIIa heparin specifically causes inactivation of a rate
limiting reactani. Factor IXa is the obvious candidate' Indeed
when fictor IXa is added after factor VIIIa an equally high burst
of thrombin formation is seen with the two inhibitors (Fig' 6)' It
seems that thrombin generation is switched on by the apPearance
of a threshold concentration of factor VIIIa but that the peak
height is determined by the amount of factor IXa available at the
moment that factor VIIIa appears. The effect of heparin on
thrombin causes retardation of factor VIII activation and so
prolongs the lag time. During the lag time heparin-Al III acts on
itt" t 
"" 
factor IXa that is available. The concentration of
factor IXa that is left at the moment of switch on, then
inhibition of thrombin generation, when triggered extrinsically,
was equal for the DS-PS mixture and for 0.05 U/ml of heparin'
From Fig.2 it is seen that the PS-DS mixture inhibits intrinsi-
cally triggeied thrombin formation again for about 50%, but that
treparin in this case inhibits significantly more (about 75%)' This
difference must be caused by inhibition at or above the level of
the intrinsic factor X activator. When the complete factor X
activating complex is used as a starter (Fig.3) the difference
between heparin and the PS/DS mixture disappears' It reappears
when the reaction is started with alone factor IXa and phos-
pholipid without factor VIIIa (Fig. a). This strongly suggests that
itt" i"tio.t of heparin on free factor IXa contributes to the
lowering of the thrombin level in intrinsic coagulation' From
"o-pa.itott 
of Figs. 2, 3 and 4 it is seen that when activated
factor VIII is absent from the triggering mixture a lag time
appears in the control experiment' Both the PS-DS mixture and
heparin prolong the lag time but heparin is more effective than
PS-DS is. When factor VIIIa is added during the lag time'
thrombin generation starts immediately' independent of the
inhibitor present (Fig.s). The amount of thrombin formed is,
however, much higher with PS-DS than with heparin' It appears
that the addition of factor vIII a switches on thrombin formation
but that the actual amount ofthrombin formed is dependent upon
the concentration of a reactant that is specifically affected by
heparin and not by PS-DS, i. e. factor IXa' That factor IX4 is rate
timiting under these circumstances is seen in the experiments
pr"r"tti"d in Fig.6 where the addition of factor IXa after
iactor VIIIa causes an increase of thrombin formation that is
essentially equal in the presence of heparin and in the presence of
the DS-PS mixture. (Note that the difference in peak height in
Fis.6 reflects the difference already existing at the moment of
faitor IXa addition.)
Discussion
It has been demonstrated that heparin, at a concentration of
0.5 U/ml completely inhibits factor X activation because no
factor X is aciivated under these circumstances (6)' We have
investigated whether factor IXa inactivation contributes to the
partial inhibition of thrombin generation seen at lower heparin
ioncentrations. Indctivation of thrombin' factor Xa and/or fac-
tor IXa may contribute to this effect. The inhibitory effect of the
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essentially different praperties of this type of drug. If the ratio of
the different activities remains (approximately) constant, like in
batches of unfiactionated heparin, each of the three tests will
indicate the same level of active material in a plasma sample.
However, then the ratios of the activities vary, such as in the case
of lorv molecular weight heparins, the results of the different tests
may no longer be compared.
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